Fakülteler / Faculties
Permanent URI for this communityhttps://hdl.handle.net/11727/1395
Browse
2 results
Search Results
Item Retinal and Choroidal Thickness Changes After Single Anti-VEGF Injection in Neovascular Age-Related Macular Degeneration: Ranibizumab vs Bevacizumab(2014) Sizmaz, Selcuk; Kucukerdonmez, Cem; Kal, All; Pinarci, Eylem Yaman; Canan, Handan; Yilmaz, Gursel; https://orcid.org/0000-0002-5877-6536; https://orcid.org/0000-0002-2589-7294; 24803153; AAB-6394-2021; AAK-6987-2021Purpose: To evaluate and compare the effects of single intravitreal injection of ranibizumab and bevacizumab on central retinal and choroidal thickness in patients with neovascular age-related macular degeneration (AMD). Methods: Forty eyes of 40 patients with neovascular AMD that underwent intravitreal injection of vascular endothelial growth factor inhibitors (anti-VEGFs) were included. Patients were randomized into 2 groups: 20 eyes received ranibizumab and 20 eyes received bevacizumab injection. Central retinal and choroidal thicknesses of all eyes at baseline and 1 month postinjection scans were measured with Fourier-domain optical coherence tomography (OCT). Student t test and Mann-Whitney U test were used to compare the data. Results: The mean central retinal thickness (CRT) showed significant decrease after single injection of ranibizumab (from 345.0 mu m to 253.5 mu m, p<0.01) and bevacizumab (from 329.5 mu m to 251.0 mu m, p<0.01) at the first month, respectively. There was no significant difference regarding the CRT change between groups (p = 0.39). The mean choroidal thickness decreased from 158.6 mu m (115-317) to 155.5 mu m (111-322) in the ranibizumab group and from 211.5 mu m (143-284) to 201.5 mu m (93-338) in bevacizumab group. The decrease was not significant between groups (p = 0.35). Conclusions: Intravitreal injection of both ranibizumab and bevacizumab provided a significant decrease in CRT; however, the agents caused no significant change in choroidal thickness. Additionally, no difference between ranibizumab versus bevacizumab was observed related to macular edema inhibition.Item Evaluation of choroidal and retinal thickness measurements in adult hemodialysis patients using spectral-domain optical coherence tomography(2016) Kal, Ali; Kal, Oznur; Eroglu, Fatma Corak; Omer, Ozlem; Kucukdonmez, Cem; Yilmaz, Gursel; 0000-0002-2589-7294; 0000-0003-3003-0756; 27626146; AAK-6987-2021; D-5308-2015Purpose: To assess the effect of hemodialysis on retinal and choroidal thicknesses using spectral-domain optical coherence tomography (SD-OCT). Methods: In this prospective interventional study, 25 hemodialysis patients (17 male, 8 female) were enrolled. All participants underwent high-speed, high-resolution SD-OCT (lambda=840 mm; 26.000 A-scans/s; 5 mu m resolution) before and after hemodialysis. Choroidal thickness was measured perpendicularly from the outer edge of the retinal pigment epithelium to the choroid-sclera boundary at the fovea and at five additional points: 500 mu m and 1000 mu m nasal to the fovea and 500 mu m, 1000 mu m, and 1500 mu m temporal to the fovea. Two masked physicians performed the measurements. Choroidal and retinal thicknesses before and after hemodialysis were compared. Results: The median choroidal thicknesses before and after hemodialysis were 182 mu m (range, 103-374 mu m) and 161 mu m (range, 90-353 mu m), respectively (P<0.001). The median retinal thicknesses were 246 mu m (range, 179-296 mu m) before and 248 mu m (range, 141-299 mu m) after hemodialysis (P>0.05). Systolic arterial pressure, diastolic arterial pressure, mean arterial pressure, heart rate, and ocular perfusion pressure significantly decreased after hemodialysis (P<0.001). Intraocular pressure did not vary significantly (P=0.540). Conclusion: Hemodialysis seems to cause a significant decrease in choroidal thickness, whereas it has no effect on retinal thickness. This significant decrease in choroidal thickness might be due to the extensive fluid absorption in hemodialysis, which could result in decreased ocular blood flow.